文献速递慢性肾脏病

晚期肾病保守肾脏管理患者决策辅助工具:一项随机预试验

A Patient Decision Aid About Conservative Kidney Management in Advanced Kidney Disease: A Randomized Pilot Trial.
PubMed 文献 · Am J Kidney Dis · 2023-02-04

该随机预试验在4个医疗中心纳入92例晚期CKD患者及56名家属,评估保守肾脏管理决策辅助工具的可接受性与可行性;患者中接受决策辅助者与医疗服务提供者讨论CKM的比例为26.4% vs 3.0%(P=0.007),家属为26.9% vs 0(P=0.02),脱落率两组无显著差异。

要点

  • 患者接受决策辅助后与提供者讨论CKM的比例为26.4% vs 3.0%(P=0.007)。
  • 家属接受决策辅助后讨论CKM的比例为26.9% vs 0(P=0.02)。
  • 患者脱落率21% vs 21%(P=1.0),家属10% vs 18%(P=0.46)。

核心结论

  • CKM决策辅助工具可行且可接受,并增加了患者及家属与医疗服务提供者对该治疗方案的讨论。
  • 该工具可能作为现有晚期CKD治疗教育工具的有用补充。

研究设计与样本

  • 随机预试验,纳入年龄≥75岁、CKD 4期或5期患者及其家属。
  • 研究于2020年8月至2021年12月在4个医疗中心开展。
  • 92例患者随机分配,86例完成初始访视(T1),其中常规护理组42例、常规护理加决策辅助组44例。
  • 56名家属入组,53名完成T1,其中常规护理组20名、常规护理加决策辅助组33名。

主要发现

  • 患者脱落率:常规护理组21% vs 常规护理加决策辅助组21%(P=1.0)。
  • 家属脱落率:常规护理组10% vs 常规护理加决策辅助组18%(P=0.46)。
  • 患者与提供者讨论CKM比例:常规护理加决策辅助组26.4% vs 常规护理组3.0%(P=0.007)。
  • 家属与提供者讨论CKM比例:常规护理加决策辅助组26.9% vs 常规护理组0(P=0.02)。

局限性

  • 参与者为相对同质的人群,可能限制普遍性。
  • 决策辅助工具聚焦于CKM,对肾脏替代治疗知识有限者可能适用性较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Available decision aids for patients about treatment of advanced chronic kidney disease (CKD) often lack information on conservative kidney management (CKM). We assessed the feasibility and acceptability of a decision aid on CKM among patients with advanced CKD and their family members. STUDY DESIGN: Randomized pilot trial. SETTING & PARTICIPANTS: Patients aged≥75 years with stage 4 or 5 CKD and their family members at 4 medical centers in the greater Seattle area between August 2020 and December 2021. INTERVENTIONS: Usual care with or without a decision aid on CKM. OUTCOME: Acceptability was assessed by attrition rates between the initial study visit (T1) and the 3-month follow-up evaluation (T3). The primary outcome and measure of feasibility was the proportion of participants who discussed CKM with a health care provider between T1 and T3. RESULTS: We randomized 92 patients of whom 86 (55.8% male; age 82±6 years; 82.6% White) completed T1-42 in the usual care arm and 44 in the usual care plus decision aid arm-and 56 family members of whom 53 (18.9% male; age 71±11 years; 86.8% White) completed T1-20 in usual care arm and 33 in the usual care plus decisions aid arm. The attrition rates were 21% versus 21% (P=1.0) for patients, and 10% versus 18% (P=0.46) for family members in the usual care versus usual care plus decisions aid arms. Receipt of the decision aid significantly increased discussion of CKM with a health care provider for patients (26.4% vs 3.0%, P=0.007) and family members (26.9% vs 0, P=0.02). LIMITATIONS: Possible limited generalizability because participants were a relatively homogenous group. The decision aid focuses on CKM and may be less applicable to those with limited knowledge of kidney replacement therapies. CONCLUSIONS: A CKM decision aid was feasible and acceptable, and increased discussion of this treatment option with health care providers. This aid may serve as a useful adjunct to the currently available educational tools on treatments for advanced CKD. FUNDING: Grant from a not-for-profit entity (National Palliative Care Research Center). TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT04919941.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Wong SPY, Oestreich T, Prince DK, et al. A Patient Decision Aid About Conservative Kidney Management in Advanced Kidney Disease: A Randomized Pilot Trial. Am J Kidney Dis. 2023. PMID: 36740038. doi:10.1053/j.ajkd.2022.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。